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of the SARA Gait and Posture
Sub-scale in Early Onset Ataxia
Tjitske F. Lawerman, Rick Brandsma, Renate J. Verbeek, Johannes H. van der Hoeven,
Roelineke J. Lunsing, Hubertus P. H. Kremer and Deborah A. Sival*
Departments of Pediatrics and Neurology, Beatrix Children’s Hospital, University Medical Center Groningen, Groningen,
Netherlands
Aim: In children, gait and posture assessment provides a crucial marker for the early
characterization, surveillance and treatment evaluation of early onset ataxia (EOA).
For reliable data entry of studies targeting at gait and posture improvement, uniform
quantitative biomarkers are necessary. Until now, the pediatric test construct of gait and
posture scores of the Scale for Assessment and Rating of Ataxia sub-scale (SARA) is
still unclear. In the present study, we aimed to validate the construct validity and reliability
of the pediatric (SARAGAIT/POSTURE) sub-scale.
Methods: We included 28 EOA patients [15.5 (6–34) years; median (range)]. For
inter-observer reliability, we determined the ICC on EOA SARAGAIT/POSTURE sub-
scores by three independent pediatric neurologists. For convergent validity, we
associated SARAGAIT/POSTURE sub-scores with: (1) Ataxic gait Severity Measurement by
Klockgether (ASMK; dynamic balance), (2) Pediatric Balance Scale (PBS; static balance),
(3) Gross Motor Function Classification Scale -extended and revised version (GMFCS-
E&R), (4) SARA-kinetic scores (SARAKINETIC; kinetic function of the upper and lower
limbs), (5) Archimedes Spiral (AS; kinetic function of the upper limbs), and (6) total SARA
scores (SARATOTAL; i.e., summed SARAGAIT/POSTURE, SARAKINETIC, and SARASPEECH
sub-scores). For discriminant validity, we investigated whether EOA co-morbidity factors
(myopathy and myoclonus) could influence SARAGAIT/POSTURE sub-scores.
Results: The inter-observer agreement (ICC) on EOA SARAGAIT/POSTURE sub-scores
was high (0.97). SARAGAIT/POSTURE was strongly correlated with the other ataxia and
functional scales [ASMK (rs = −0.819; p < 0.001); PBS (rs = −0.943; p < 0.001);
GMFCS-E&R (rs = −0.862; p < 0.001); SARAKINETIC (rs = 0.726; p < 0.001);
AS (rs = 0.609; p = 0.002); and SARATOTAL (rs = 0.935; p < 0.001)]. Comorbid
myopathy influenced SARAGAIT/POSTURE scores by concurrent muscle weakness,
whereas comorbid myoclonus predominantly influenced SARAKINETIC scores.
Conclusion: In young EOA patients, separate SARAGAIT/POSTURE parameters reveal
a good inter-observer agreement and convergent validity, implicating the reliability of
the scale. In perspective of incomplete discriminant validity, it is advisable to interpret
SARAGAIT/POSTURE scores for comorbid muscle weakness.
Keywords: early onset ataxia, SARA, gait, validity, myopathy, muscle weakness, coordination, balance
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INTRODUCTION
Pediatric ataxic gait and posture- assessment provides an
important instrument to identify children and young adults
with indisputable EOA (Brandsma et al., 2016a; Lawerman
et al., 2016). The availability of validated gait and posture-
biomarkers in children is also important for the entry of high
quality data in international EOA databases (Durr, 2015;
Brandsma et al., 2016a; Lawerman et al., 2016) and also for
the evaluation of treatment (Romano et al., 2015), especially
when the training of core-muscles is involved (such as by
exergame-training) (van Diest et al., 2016; Schatton et al.,
2017). In young, often disabled, EOA patients with limited
concentration and physical endurance, optimally applicable
gait and posture biomarkers are characterized as: non-invasive,
quick and easy, compatible with adult parameters, reliable and
also associated with a good construct validity (Schmidt and
Embretson, 2003; Saute et al., 2012). Until now, insight in the
validity of clinically available gait and posture- biomarkers
is incomplete. The SARA is described as a reliable, quickly
assessable, and non-invasive rating scale for patients with
ataxia (Schmitz-Hubsch et al., 2006). SARA scores consist of
summed: gait and posture- (SARAGAIT/POSTURE measuring
gait, stance, sitting performances), kinetics (SARAKINETIC)
and speech (SARASPEECH) sub-scores (Schmitz-Hubsch
et al., 2006). In EOA, we aimed to investigate the construct
validity of the pediatric SARAGAIT/POSTURE sub-scale
scores.
For the investigation of the EOA SARAGAIT/POSTURE
construct validity, it is important to realize two points. First,
it is important to realize that the SARA was originally
designed and validated as a complete, total score in the
domains of gait/posture, kinetics, and speech (Schmitz-Hubsch
et al., 2006). However, under the assumption that the SARA
sub-scale scores SARAGAIT/POSTURE and SARAKINETIC measure
cerebellar functioning in different domains (i.e., vermis and
anterior lobe and cerebellar hemispheres, respectively), we
hypothesized that the SARAGAIT/POSTURE sub-scale could be
separately validated. Second, it is important to realize that
the SARA was originally designed and validated in adult
patients with AOA (Schmitz-Hubsch et al., 2006). However,
due to the short clinical assessment time and good score
reproducibility, the scale was soon applied in children too
(Brandsma et al., 2014a, 2016b; Hartley et al., 2015; Reetz
et al., 2015). Before SARA scores can be analogously interpreted
in AOA and EOA patients, it is thus important to take the
effect of potential group differences into account. In comparison
with the AOA patient group, EOA patients may reveal a
Abbreviations: AOA, adult onset ataxia; AS, Archimedes Spiral; ASMK, Ataxia
Severity Measurement according to Klockgether; EOA, early onset ataxia (starting
before the 25th year of life); FA, Friedreich’s ataxia; GMFCS-E&R, Gross Motor
Function Classification Scale- extended and revised version; ICARS, International
Cooperative Ataxia Rating Scale; MF, muscle force; MFLE, MF z-score of lower
extremities; MFProx, MF z-scores of proximal muscles; MFTOTAL, total MF z-score;
MFUE, MF z-score of upper extremities; MU, muscle ultrasound; PBS, Pediatric
Balance Scale; SARA, Scale for Assessment and Rating of Ataxia; SARATOTAL,
summed total SARA score; SARAGAIT/POSTURE, the summed SARA sub-scores for
gait, stance and sitting; SARAKINETIC, SARA kinetic sub-score.
large variety of disorders, with a heterogeneous phenotypic
presentation and co-morbidity (such as myopathy and/or
myoclonus). This explains why SARA score characteristics
can differ between AOA and EOA patient groups (Sival and
Brunt, 2009; Sival et al., 2011; Brandsma et al., 2014a, 2016b).
For instance, in AOA patients, total SARA scores relate with
ataxia as one single factor [i.e., ‘ataxia’ (Schmitz-Hubsch et al.,
2006)]. This is contrasted by total SARA scores in EOA
patients, which are also attributed to: (1) pediatric age (i.e.,
cerebellar maturation; Largo et al., 2003; Sival and Brunt, 2009;
Brandsma et al., 2014a), (2) comorbid muscle weakness [in
FA (Sival et al., 2011)], and (3) comorbid movement disorders
(Brandsma et al., 2016b).
In children and young adults with EOA, we thus aimed to
investigate the construct validity of the SARAGAIT/POSTURE
sub-scale. Under the premise that parameters for
SARAGAIT/POSTURE would depend on the integrated cerebellar
processing of visual, vestibular, and sensory signals of the limbs
and trunk (Sival, 2012; Delabasita et al., 2016; Takakusaki,
2017), SARAGAIT/POSTURE sub-scales would be expected to
correlate with biomarkers for dynamic and passive balance,
such as: the scale for ASMK [dynamic balance (Klockgether
et al., 1998)] and the PBS (static balance; Franjoine et al.,
2010). Additionally, we reasoned that clinically meaningful
and effective SARAGAIT/POSTURE sub-scores would relate with
a validated, age-related classification system for functional
motility in children, such as the GMFCS (Palisano et al.,
1997) – the extended and revised version (E&R; Palisano et al.,
2008), which is originally designed for children with cerebral
palsy. Furthermore, accurate kinematics for SARAGAITPOSTURE
performances would also correlate with biomarkers for
kinetic-limb function, such as: SARAKINETIC (upper and
lower limbs) and AS [upper limb kinetic scores (Trouillas
et al., 1997)]. Finally, effective EOA SARAGAIT/POSTURE
scores would be expected to correlate with SARATOTAL.
Strong and significant correlations would underpin a good
convergent validity of SARAGAIT/POSTURE sub-scale scores.
Absent influence by EOA co-morbidity factors (such as muscle
weakness and/or myoclonus) on the scores would underpin
sufficient discriminant validity of the SARAGAIT/POSTURE
sub-scale.
In the present study, we thus aimed to elucidate the construct
validity and reliability of EOA SARAGAIT/POSTURE sub-scale
scores in children and young adults.
MATERIALS AND METHODS
The Medical Ethical Committee of the University Medical
Center Groningen (UMCG), Netherlands, approved the study
(METc 2011/165). According to the Dutch medical ethical
law, both parents and children older than 12 years of age
provided written informed consent. Children younger than
12 years of age provided assent. All subjects gave written
informed consent in accordance with the Declaration of
Helsinki. The protocol was approved by the ‘The Medical
Ethical Committee of the University Medical Center Groningen
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(UMCG), Netherlands’. In the absence of preceding pediatric
data for a power calculation, we performed a prospective,
explorative study.
Patients
Over a 5 year period (2011–2016), we have collected a complete
cohort of EOA children that visited the pediatric neurology
ward at UMCG (Brandsma et al., 2016b). From this cohort,
we included patients that fulfilled the criteria for “distinct
ataxia,” characterized by: EOA (initiation of ataxia before the
25th year of life) and unanimous recognition of ataxia as
the main movement disorder by three independent pediatric
neurologists and/or unanimous recognition of ataxia as part
of the movement disorder by three independent pediatric
neurologists and confirmation of the ataxic phenotype by the
OMIM database1. Patients were excluded when they were unable
to understand the required motor function tasks for the present
study.
We included 28 EOA patients [median age 15.5 (range:
6–34) years]. The response rate was 100%. In 24/28 (86%)
patients, ataxia was independently recognized as the main
movement disorder by all three pediatric neurologists.
The other 4 of 28 (14%) patients were included on basis
of unanimous phenotypic ataxia recognition (primary or
secondary features) and diagnostic confirmation that ataxia
is involved according to the OMIM database1. Underlying
metabolic or genetic diagnoses (n = 24/28) included: FA
(n = 8), GOSR2-mutation (n = 4), ataxia with vitamin E
deficiency (AVED; n = 2), CACNA1A-mutation (n = 2),
Ataxia Telangiectasia (n = 1), Joubert syndrome type 23
(n= 1), Kearns Sayre syndrome (KSS; n= 1), MHBD-deficiency
(n = 1), NARP-mutation (n = 1), Niemann–Pick type
C (n= 1), Poretti Bolthauser syndrome (n = 1), and SCA5
(n = 1). The remaining four patients remained undiagnosed,
despite whole exome sequencing. We assigned patients to
‘myopathic’ or ‘myoclonic’ EOA subgroups, when myopathy
or myoclonus was described in the medical records as major
comorbid EOA pathology and when myopathic or myoclonic
features are phenotypically described in the OMIM database1.
The ‘myopathic’ co-morbidity subgroup (EOAMYOPATHIC)
involved 11 patients with FA (n = 8); KSS (n = 1); MHBD
(n = 1); and NARP (n = 1) gene-mutations. The ‘myoclonic’
co-morbidity subgroup (EOAMYOCLONIC) involved four
GOSR2 patients with spontaneous, multifocal myoclonus
and action-induced enhancement, at the upper extremities,
face and lower extremities (van Egmond et al., 2014). In all
four EOAMYOCLONIC patients, the medical records described
clinical presence of comorbid myoclonus, which was also
assessable during videotaped motor task performances (in 3
of 4 patients by 2 of 3 observers and in 1 patient by 1 of 3
observers). The remaining ‘other’ subgroup involved 13 patients,
with neither ‘myopathic’ nor ‘myoclonic’ co-morbidity. In all
patients, we reported the presence of secondary movement
1Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of
Genetic Medicine, Johns Hopkins University (Baltimore, MD, United States), 24-
12-2016. World Wide Web: http://omim.org/.
disorder features when at least 2 of 3 independent observers
had assessed the same secondary feature, in accordance
with the clinical phenotype. For patient characteristics, see
Table 1.
Assessments
In pediatric EOA patients, we investigated the
SARAGAIT/POSTURE construct validity by determining the:
(1) inter-observer reliability, (2) convergent validity, and (3)
discriminant validity.
Inter-Observer Reliability
For the inter-observer reliability, we determined the Interclass
Correlation Coefficient (ICC) of the SARAGAIT/POSTURE video-
ratings by three independent pediatric neurologists, according
to the official SARA guidelines (Schmitz-Hubsch et al.,
2006).
Convergent Validity
For convergent validity, we correlated SARAGAIT/POSTURE
[i.e., summed gait, stance, and sitting sub-scale scores
(Schmitz-Hubsch et al., 2006] with other rating scale
scores for coordinated motor function, including ASMK
[dynamic balance (Klockgether et al., 1998)]; PBS [static
balance (Franjoine et al., 2010)]; GMFCS-E&R (Palisano
et al., 1997, 2008), Dutch version2; SARAKINETIC (kinetic
function of upper and lower limbs) (Schmitz-Hubsch et al.,
2006); AS (kinetic function of the upper limbs (Trouillas
et al., 1997) and, finally also SARATOTAL [summed ataxia
scores in gait/posture, kinetic, and speech domains (Schmitz-
Hubsch et al., 2006)]. To prevent unnecessary test burden
and exhaustion of the patient, we planned investigations
during successive hospital visits for clinical reasons. For
latent time intervals between tests, see Supplementary
Table I.
For information about SARA, AMSK, PBS, GMFCS-E&R,
and AS testing, see Appendix B. The ASMK (Klockgether
et al., 1998) and GMFCS (Palisano et al., 2008) data
were compiled from patient records and interviews. The
PBS (Franjoine et al., 2010) scores were provided by one
independent investigator, blinded for the results of the
other test scores. In children, the reliability of this method
was shown to be very high (ICC.997) (Franjoine et al.,
2003).
Discriminant Validity
For discriminant validity, we determined the potentially
confounding influence by comorbid EOA factors, consisting
of (1) myopathic muscle weakness and (2) myoclonus on
the SARAGAIT/POSTURE scores. We assessed MF by hand held
dynamometry (CITEC; C.I.T. Technics, Haren, Groningen,
Netherlands) (Beenakker et al., 2001). We determined summed
total muscle force (MFTOTAL), upper extremity muscle force
2Nederlandse vertaling 2009 NetChild Network for Childhood Disability Research,
Utrecht, Netherlands, 15-10-2017. World Wide Web: https://canchild.ca/
system/tenon/assets/attachments/000/000/067/original/GMFCS-ER_Translation-
Dutch.pdf.
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(MFUE), lower extremity muscle force (MFLE), and proximal
muscle force (MFPROX). For detailed information of the tested
muscles per item, see Appendix B. As the normality of pediatric
MF depends on age, weight and sex, we expressed outcomes
as Z-scores from the corrected normal values (Beenakker,
2005).
As ‘ataxia’ and/or ‘myoclonus’ could theoretically prohibit
accurate muscle activation and/or MF assessment, we controlled
whether paretic measurements (Z-scores < −2 SD) were
consistent with MU abnormalities of the same muscles. MU
images (of the biceps, rectus femoris, and tibial anterior muscles)
were obtained in accordance with a standard protocol and
settings (Sival et al., 2011; Brandsma et al., 2012). Two MU
experts independently classified MU images as: ‘myopathic,’
‘neuropathic,’ ‘combined’ (i.e., myopathic and neuropathic) or
‘none’ (in absence of myopathic or neuropathic abnormalities).
In a previous publication, we have shown the reliability of
this method (Brandsma et al., 2014b). Myopathic abnormalities
are characterized by homogeneously increased MU density
and/or muscle atrophy in a proximal to distal distribution.
Neurogenic muscle abnormalities are characterized by MU
inhomogeneity.
Correlations and Comparisons
For assessment of convergent validity, we correlated
SARAGAIT/POSTURE (Schmitz-Hubsch et al., 2006) with the scores
from: ASMK (dynamic balance), PBS (static balance), GMFCS-
E&R, AS, SARAKINETIC, and SARATOTAL. For the assessment
of discriminant validity, we correlated SARAGAIT/POSTURE
sub-scale scores with MF Z-scores. The correlations between
SARAGAIT/POSTURE scores and MF Z-scores were subsequently
stratified for EOA subgroups with and without comorbid
myopathy. To evaluate the potential influence by myopathy
and myoclonus on the SARAGAIT/POSTURE scores, we calculated
the relative contribution of SARAGAIT/POSTURE to the total
SARA scores (i.e., SARAGAIT/POSTURE %sub-score = [median
gait score/median total score] × 100%), and we compared
outcomes between myopathic versus non-myopathic and
myoclonic versus non-myoclonic subgroups. For further
insight, we also compared the SARAKINETIC sub-score
percentages (i.e., SARAKINETIC %sub-score = [median
kinetic score/median total score] × 100%) between all
subgroups.
Statistical Analysis
We performed statistical analysis using SPSS statistics 22.0.
We determined normality of age, time differences between
assessments, median SARA scores, ASMK scores, PBS
scores, GFMCS-E&R scores, AS scores and MF z-scores
both graphically and by the Shapiro–Wilk test. Correlation
results were interpreted by the Evans criteria [<0.20 very
weak; 0.2 to 0.39 weak; 0.40 to 0.59 moderate; 0.6 to 0.79
strong, and 0.8 to 1 as very strong (Evans, 1996)]. All statistical
tests were two-sided. p-values <0.05 were considered as
statistically significant. We applied the Bonferroni correction
to adjust the p-value for multiple comparisons on the same
data.
RESULTS
Scale Descriptives and Inter-Observer
Agreement
For descriptives of SARA, ASMK, PBS, GMFCS-E&R, and
MF scores, see Table 2. The included patients revealed a
binary distribution of ASMK scores (ASMK scores 1 and 3),
corresponding with ambulant and non-ambulant function,
respectively. There was no association between cross-sectional
SARA scores and age or disease duration (Spearman’s Rho,
rs = 0.110; p = 0.58; and rs = −0.108; p = 0.59, respectively).
For missing data, see Appendix A. The inter-observer agreement
(ICC) of SARAGAIT/POSTURE, SARATOTAL and SARAKINETIC was
high (0.97; 0.97; and 0.88, respectively).
Convergent Validity: The Association
between SARA Scores, Ataxia Severity
Measurement Scale (ASMK), Balance




SARAGAIT/POSTURE and SARATOTAL scores were (very) strongly
associated with ASMK, PBS, GMFCS-E&R, SARAKINETIC, and
AS scores; see Table 3 and Figure 1. For comparison of SARA
scores between the ambulant subgroup (AMSK score 1) and the
non-ambulant subgroup (AMSK score 3), see Supplementary
Table II. SARAGAIT/POSTURE sub-analysis for active balance
(SARAWALKING) and passive balance (SARASTANCE/SITTING)
revealed high correlations: (1) between SARAWALKING items
and ASMK scores, and (2) between SARASTANCE/SITTING and
PBS scores (Spearman’s Rho: rs = 0.867 and rs = 0.917,
respectively; p < 0.001). SARAGAIT/POSTURE was also correlated
with SARAKINETIC (kinetic function of the upper and lower
limbs; rs = 0.726; p < 0.001) and with AS (kinetic function of
the upper limbs; rs = 0.609; p= 0.002). See Table 3 and Figure 1.
Discriminant Validity
(a) Association between SARA scores and muscle force
In the total EOA group, SARAGAIT/POSTURE and SARATOTAL
revealed strong correlations with muscle weakness of the lower
extremities (MFLE) and proximal muscles (MFPROX) (MFLE
and MFPROX). In the ‘myopathic’ subgroup, SARAGAIT/POSTURE
and SARATOTAL revealed very strong correlations with muscle
weakness of the lower extremities. For all r-values, see Table 4
and Figure 2. In the myopathic subgroup, we controlled
whether dynamometry and MU assessments corresponded with
myopathic pathology (see Table 5). MU analysis revealed pure
myopathic changes in 60% and combined myopathic/neurogenic
changes in 30%. In the non-myopathic subgroup, the above
mentioned correlations with muscle weakness were absent. This
group revealed one child with neuropathic alterations and
substantial muscle weakness, revealing a similar association
between SARAGAIT/POSTURE scores and muscle weakness as the
Frontiers in Human Neuroscience | www.frontiersin.org 5 December 2017 | Volume 11 | Article 605
fnhum-11-00605 December 11, 2017 Time: 13:10 # 6
Lawerman et al. Construct Validity of SARA Gait Scores
myopathic group. For subgroup correlations, see Table 4 and
Figures 2A–F.
(b) Association between SARA scores, myopathy and
myoclonus
Comparing EOA subgroups, revealed the highest
%contribution of the SARAGAIT/POSTURE to the SARATOTAL
(i.e., SARAGAIT/POSTURE/SARATOTAL × 100%) in the myopathic
subgroup (Mann–Whitney U, p = 0.038), see Figure 3.
Comparing the %contribution of the SARAGAIT/POSTURE
to SARATOTAL between myoclonic versus non-myoclonic
subgroups, revealed a significantly lower %contribution
of the SARAGAIT/POSTURE in the myoclonic subgroup














Median (p25–p75) 14.5 (9.1–25.6) 27 (14.8–30.5) 11 (8.5–18) 0.022∗ 13.5 (10.1–18.8) 15.1 (8.7–27.8) 0.694
Min–max 5–34.5 5.3–34.5 5–29.8 9–20.5 5–34.5
Gait/posture
Median (p25–p75) 6 (4–14.5) 15 (5–18) 5 (3.3–6.5) 0.004∗∗ 5 (3.3–6.8) 6 (4–15) 0.306
Min–max 3–18 4–18 3–15 3–7 3–18
Kinetic#
Median (p25–p75) 5.3 (3.6–9.2) 8 (4.3–10) 5 (3.3–8) 0.144 6 (4.6–10.4) 5.3 (3.5–9.2) 0.469
Min–max 1.5–11.5 1.5–10.5 1.5–11.5 4.5–11.5 1.5–10.5
ASMK scores
Median (p25–p75) 1 (1–3) 3 (1–3) 1 (1–1) 0.009∗∗ 1 (1–1) 1 (1–3) 0.117
Min–max 1–3 1–3 1–3 1–1 1–3
PBS scores
Median (p25–p75) 42 (4–50) 3.5 (0–43.1) 45 (25.3–50.4) 0.005∗∗ 43.8 (34.6–48.8) 32.3 (3.8–50) 0.476
Min–max 0–55 0–50 4–55 32–50 0–55
GMFCS-E&R
Median (p25–p75) 1 (1–3) 4 (2–4) 1 (1–2) 0.000∗∗ 1,5 (1–2) 2 (1–4) 0.243
Min–max 1–5 2–5 1–4 1–2 1–5
Archimedes spiral
Median (p25–p75) 1.5 (1–2.9) 2 (0.8–3) 1 (1–2.9) 0.606 2.3 (1.3–3.6) 1 (1–2.8) 0.279
Min–max 0–4 0–4 0–4 1–4 0–4
MF (z-scores)
Median (p25–p75) −1.2 (−3.5 to −0.4) −3.2 (−4.8 to −1.3) −0.6 (−1.3 to −0.2) 0.004∗∗ −0.6 (−1.9 to −0.1) −1.3 (−4.2 to −0.5) 0.245
Min–max −5.9 to 0.4 −5.9 to −0.7 −4.5 to 0.4 −2.2 to −0.1 −5.9 to 0.4
SARATOTAL, total score of the Scale for Assessment and Rating of Ataxia; ASMK, Ataxia Severity Measurement according to Klockgether; PBS, Pediatric Balance Scale;
GMFCS-E&R, Gross Motor Function Classification Scale – extended and revised version; MF, total muscle force; EOAMYOPATHIC, EOA with reported comorbid myopathy;
EOANON-MYOP, EOA with absent comorbid myopathy (EOAMYOCLONUS + EOAOTHER); EOAMYOCL, EOA with reported comorbid myoclonus; EOANON-MYOCL, EOA with
absent myoclonus (EOAMYOPATHIC + EOAOTHER); p25–p75, lower and upper quartile; min, minimum; max, maximum; # = scores are normally distributed; p-values
∗p < 0.05, ∗∗p < 0.01 (Mann–Whitney U-test). The EOAMYOPATHIC subgroup reveals higher SARATOTAL, SARAGAIT/POSTURE and ASMK scores and lower PBS and muscle
force scores than EOANON-MYOP. The EOAMYOCL and EOANON-MYOCL subgroups did not significantly differ.
TABLE 3 | Correlations between SARA scores and other measurements of coordination.
SARAGAIT/POSTURE SARATOTAL ASMK PBS GMFCS-E&R SARAKINETIC# AS
SARAGAIT/POSTURE − 0.935∗ 0.815∗ −0.943∗ −0.862∗ 0.726∗ 0.609∗
SARATOTAL 0.935∗ − 0.772∗ −0.911∗ 0.767∗ 0.887∗ 0.805∗
ASMK 0.815∗ 0.772∗ − −0.817∗ 0.848∗ 0.474 0.489
PBS −0.943∗ −0.911∗ −0.817∗ − −0.870∗ −0.685∗ −0.640∗
GMFCS-E&R −0.862∗ 0.767∗ 0.848∗ −0.870∗ − 0.510 0.461
SARAKINETIC# 0.726∗ 0.887∗ 0.474 −0.685∗ 0.510 − 0.846∗
AS 0.609∗ 0.805∗ 0.489 −0.640∗ 0.461 0.846∗ −
SARATOTAL, total score of the Scale for Assessment and Rating of Ataxia; SARAGAIT/POSTURE, SARA gait and posture sub-scales; ASMK, Ataxia Severity Measurement
according to Klockgether; PBS, Pediatric Balance Scale; GMFCS-E&R, Gross Motor Function Classification Scale – extended and revised version; AS, Archimedes Spiral;
# = Scores are normally distributed; values represent Spearmans Rho; ∗correlations are considered statistically significant with p ≤ 0.002 (Bonferroni correction for 21
comparisons). SARAGAIT/POSTURE and SARATOTAL correlated strongly with other parameters for coordination measurement.
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FIGURE 1 | Correlation between SARAGAIT/POSTURE sub-scores and ASMK, PBS scores, GMFCS-E&R, SARAKINETIC, and AS. The x-axis indicates ASMK scores
(A), PBS scores (B), GMFCS-E&R classification (C), SARAKINETIC scores (D), AS scores (E). The y-axis indicates the SARAGAIT/POSTURE scores (A–E).
SARAGAIT/POSTURE scores were associated with ASMK, PBS scores, GMFCS-E&R, SARAKINETIC, and AS scores. SARA, Scale for Assessment and Rating of Ataxia;
ASMK, Ataxia Severity Measurement according to Klockgether; PBS, Pediatric Balance Scale; GMFCS-E&R, Gross Motor Function Classification Scale-the
extended and revised version; AS, Archimedes Spiral.
(Mann–Whitney U, p = 0.018, see Figure 3). Conversely,
we observed the highest %contribution of the SARAKINETIC
to SARATOTAL (i.e., SARAKINETIC/SARATOTAL × 100%) in
the myoclonic subgroup (Mann–Whitney U, p = 0.028), see
Figure 3. For subgroup comparisons between myoclonic,
myopathic, and other (non-myoclonic and non-myopathic), see
Figure 4.
DISCUSSION
In children and young adults with EOA, we aimed to investigate
the construct validity of SARAGAIT/POSTURE sub-scores.
SARAGAIT/POSTURE sub-scores revealed a high inter-observer
agreement (ICC) and were strongly associated with other
TABLE 4 | Correlations between SARA scores and muscle force.
Total group EOAMYOPATHIC EOANON−MYOP
r-values r-values r-values
SARATotal-MFTotal∧ −0.719∗∗ −0.903∗∗ −0.308
SARAGAIT/POSTURE-MFLE∧ −0.724∗∗ −0.882∗ −0.320
SARAGAIT/POSTURE-MFProx∧ −0.690∗∗ −0.894∗∗ −0.248
SARAKINETIC#-MFUE# −0.574∗ −0.619 −0.410
SARAKINETIC# -MFProx∧ −0.516 −0.564 −0.293
EOAMYOPATHIC, EOA with reported comorbid myopathy; EOANON-MYOP, EOA with
absent comorbid myopathy (EOAMYOCLONUS + EOAOTHER); MF, muscle force; LE,
lower extremities; UE, upper extremities; Prox, proximal muscles; SARATOTAL, total
SARA score; SARAGAIT/POSTURE, SARA gait sub-score; SARAKINETIC, SARA kinetic
subscore; # = Scores are normally distributed; ˆ = Spearmans Rho (r-value = rS-
value); correlations are considered statistically significant with p < 0.01 (Bonferroni
correction for five comparisons). ∗p < 0.01; ∗∗p < 0.001. In the EOAMYOPATHIC
subgroup, SARATOTAL and SARAGAIT/POSTURE scores correlate with MF.
quantitative scales for coordinative motor function, such as:
active and static balance (ASMK, PBS), kinetic limb performances
(SARAKINETIC, AS) and total ataxia scores (SARATOTAL).
Furthermore, we also observed a strong correlation between
SARAGAIT/POSTURE sub-scores and the classification levels
of the GMFCS (E&R), which is originally designed for the
assessment of functional motility in children with cerebral palsy
(Palisano et al., 1997, 2008). The discriminant validity of the
SARAGAIT/POSTURE subscale between the measurement of ataxia
and co-morbidity factors (muscle weakness and myoclonus)
was incomplete. In children and young adults with EOA, we
conclude that SARAGAIT/POSTURE scores are reliable. However,
SARAGAIT/POSTURE parameters discriminate insufficiently
between the influence by ataxia and muscle weakness. This
implicates that gait and posture scores should be interpreted
in homogeneous EOA subgroups that take comorbid muscle
weakness into account.
In previous EOA studies, we have shown that tools for the
assessment of ataxic gait may contribute to the early recognition
of indisputable EOA in young patients (Lawerman et al., 2016).
Furthermore, well-validated clinical biomarkers for EOA gait
and posture assessment are useful for the evaluation of pediatric
treatment strategies, targeting at the training of core-muscle
function (van Diest et al., 2016; Schatton et al., 2017). In
the present study, we observed an excellent inter-observer
agreement (ICC) on SARAGAIT/POSTURE sub-scores, which was
in the same range as SARATOTAL and SARAKINETIC sub-scores.
These SARATOTAL outcomes are in agreement with previously
published ICC data in adult patients with predominantly AOA
phenotypes (Schmitz-Hubsch et al., 2006).
We determined convergent validity of SARAGAIT/POSTURE
sub-scores under the premise that all ataxic gait parameters
for walking, standing, and balancing would depend on the
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FIGURE 2 | Correlation between SARA scores and MF in EOA patients. (A,D) Represent outcome data in all patients. (B,E) Represent outcome data in
non-myopathic patients. (C,F) Represent outcome data in myopathic patients. Orange markers represent patients with abnormal MU characteristics (by expert
opinion). (A–C) The x-axis indicates MFTOTAL z-scores; the y-axis indicates SARATOTAL scores. (D–F) The x-axis indicates MFLE z-scores; the y-axis indicates
SARAGAIT/POSTURE scores. rs values are presented in case of significant correlations. SARA, Scale for Assessment and Rating of Ataxia; MF, muscle force; LE, lower
extremities. In heterogeneous EOA patients, the association between SARA scores and MF is attributed to outcomes of myopathic patients.
same integrated cerebellar processing of sensory, visual, and
vestibular signals (Takakusaki, 2017) with upper- and lower-
limb and trunk motor performances (Sival, 2012; Delabasita
et al., 2016). We thus hypothesized that the construct validity
of SARAGAIT/POSTURE could be reflected by the association
with other coordinative motor function tests requiring cerebellar
integration of multimodal signals. Accordingly, we observed
that SARAGAIT/POSTURE sub-scores were strongly associated with
the tested parameters for coordinated motor function. The
SARAGAIT/POSTURE items for active and passive balance were
strongly related with ASMK and PBS scores and also with
GFMCS classifications, implicating that the closely associated
test objectives have a functional significance. Furthermore,
SARAGAIT/POSTURE scores were also correlated with kinetic
functions of the upper and lower extremities, which can be
understood by the fact that gait kinetics (including arm swing,
turning, balance and tandem -stance and -gait performances)
also require accurate limb kinetics. Finally, SARAGAIT/POSTURE
scores appeared strongly associated with SARATOTAL scores.
Although correlated, SARAGAIT/POSTURE and AS scores revealed
the lowest correlation. In perspective of the differences in
tested cerebellar domains (vermis versus hemispheres) and the
differences regarding motor function tasks (gross versus fine
motor function tasks), the lower correlation is in accordance
with our expectations. As focal cerebellar damage was excluded
from the present study group inclusion, one could attribute
the above mentioned correlations between different cerebellar
domains and/or motor function tasks to global functional
pathology of the cerebellum. In young, ataxic EOA patients
without focal cerebellar lesions, these results may thus implicate
that SARAGAIT/POSTURE scores can provide a global impression
of the total ataxia-severity. When ambulant EOA children
without focal lesions are too young (<4 years of age) or lack
the motivation and/or concentration to complete all SARA
motor task performances, SARAGAIT/POSTURE parameters could
theoretically provide a fast and easy biomarker to estimate
ataxia-progression. Altogether, in children and young adults with
distinct EOA features, SARAGAIT/POSTURE can reliably measure
‘ataxic’ gait severity and may also provide a global impression of
the total ataxia severity.
We obtained the above mentioned results under the premise
that SARA and other coordination scales measure the same
objective. However, as already stated for the AS, this is
not necessarily correct, as the other biomarkers (such as
for active and passive balance, and kinetic function) may
measure more than the objective ‘ataxia,’ alone. This implicates








n = 6 (60%)
Neurogenic muscle
abnormalities
n = 4 (29%)∗
Combined
myopathic/neurogenic muscle
abnormalities None of the
above
n = 3 (30%)
n = 1 (10%)
n = 10 (71%)
EOAMYOPATHIC, EOA with reported comorbid myopathy; EOANON-MYOP, EOA
with absent comorbid myopathy (EOAMYOCLONUS + EOAOTHER); ∗corresponding
diagnoses were: ataxia telangiectasia (n = 1). Nieman–Pick’s disease (n = 1) and
unknown (n = 2).
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FIGURE 3 | Influence of myopathy and myoclonus on SARA %sub-scores. The x-axis represents the EOA phenotypes (myopathic versus non-myopathic, and
myoclonic versus non-myoclonic). The y-axis represents the median SARAGAIT/POSTURE %sub-score (i.e., [SARAGAIT/POSTURE sub-score/median total
score] × 100%, A,C); and the median SARAKINETIC %sub-score (i.e., [median SARAKINETIC score/median total score] × 100%, B,D). Boxes represent lower quartile,
median and upper quartile; whiskers represent the minimum and maximum relative %sub-score. SARAGAIT/POSTURE, SARA gait and posture sub-score;
SARAKINETIC, SARA kinetic sub-score. Comparing the %contribution of the SARAGAIT/POSTURE to SARATOTAL between myopathic versus non-myopathic subgroups,
revealed a significantly higher %contribution of the SARAGAIT/POSTURE in the myopathic subgroup (A), whereas the %contribution of the SARAKINETIC was not
significantly different between both groups (B). Comparing the %contribution of the SARAKINETIC to SARATOTAL between myoclonic versus non-myoclonic
subgroups, revealed a significantly higher %contribution in the myoclonic subgroup (C), whereas the %contribution of the SARAGAIT/POSTURE revealed a significantly
lower %contribution in the myoclonic subgroup (D).
FIGURE 4 | Comparison of relative SARA %sub-scores between co-morbidity subgroups. The x-axis represents the EOA phenotypes [myopathic, myoclonic, and
other (non-myopathic and non-myoclonic)]. The y-axis represents: (A) the median SARAGAIT %sub-score (i.e., [SARAGAIT score/median total score] × 100%) and (B)
the median SARAKINETIC %sub-score (i.e., [median SARAKINETIC score/median total score] × 100%). Boxes represent lower quartile, median and upper quartile;
whiskers represent the minimum and maximum relative %-sub-score. SARAGAIT/POSTURE, SARA gait and posture sub-score; SARAKINETIC, SARA kinetic sub-score.
Myoclonic EOA phenotypes reveal a relatively smaller %SARAGAIT than %SARAKINETIC sub-scores compared to the other subgroups.
that other factors than ataxia could theoretically influence
SARAGAIT/POSTURE scores. For instance, in previous studies,
we have shown that the age of the child (i.e., cerebellar
maturation) has an influence on SARA scores (Sival and Brunt,
2009; Brandsma et al., 2014a). Although mean age-related
effects are comparatively small in relation to pathologic SARA
scores in ataxic patients, the Childhood Ataxia and Cerebellar
Group of the European Pediatric Neurology Society has recently
shown that children younger than 8 years of life can also
reveal considerable variation in SARATOTAL scores, which may
affect the interpretation of the longitudinal scores (Lawerman
et al., 2017). However, as the variation of SARAGAIT/POSTURE
sub-scores in young children appeared much smaller (Lawerman
et al., 2017), one could use the SARAGAIT/POSTURE sub-scale
as an internal control to discriminate between physiological
age-related and ataxia effects on the SARATOTAL scores.
To elucidate the SARAGAIT/POSTURE test construct, we also
investigated the potential effects of co-morbidity factors on
the SARAGAIT/POSTURE sub-scores. SARAGAIT/POSTURE and
SARATOTAL scores revealed an incomplete discriminant validity
between ataxia and comorbid ‘muscle weakness.’ Although
this does not automatically implicate a causal relationship,
absence of a relationship between muscle weakness and
SARAGAIT/POSTURE and SARATOTAL scores cannot be assumed,
either. For instance, when the child has difficulties to raise
an arm against gravity, or when the child has just sufficient
MF to walk with support, muscle weakness is likely to
affect the scores. Furthermore, in case of limiting muscle
weakness to execute the SARA rating scale task, maximal
scores should be given. In the latter case, ataxia itself has
not determined the score, but limiting muscle weakness
instead. This implicates that the discriminant validity of SARA
GAIT/POSTURE sub-scores between muscle weakness and ataxia is
incomplete.
Frontiers in Human Neuroscience | www.frontiersin.org 9 December 2017 | Volume 11 | Article 605
fnhum-11-00605 December 11, 2017 Time: 13:10 # 10
Lawerman et al. Construct Validity of SARA Gait Scores
Analyzing the patient inclusion of the myopathic EOA
cohort, revealed a majority of patients with FA. This underpins
our previously reported study data on the association
between muscle weakness and ataxia scores in FA children
(Sival et al., 2011). Interestingly, in another FA cohort,
this association between SARA scores and muscle weakness
was not reported (Bürk et al., 2009). However, in the
latter study, MF Z-scores were not available, implicating
that exact correlations cannot be made. Furthermore, one
should be aware that correlations between muscle weakness
and SARA scores would require patient sub-groups with
sufficient variety in MF. For example, in homogeneous
EOA groups with normal physiological muscle strength,
the influence by muscle weakness on SARA scores would
not be addressed. Similarly, in homogeneous EOA groups
with severely progressed muscle weakness (represented by
non-ambulant patients), plateauing SARA scores would also
obscure an association with muscle weakness. These results
implicate that it is advisable to obtain SARAGAIT/POSTURE
scores in homogeneous EOA subgroups and to stratify
outcomes for substantial variations in muscle weakness.
Finally, we investigated the EOA influence of comorbid
myoclonus on SARAGAIT/POSTURE sub-scores. In the comorbid
myoclonus subgroup, the percentage (%) contribution of
SARAGAIT/POSTURE to SARATOTAL scores was low compared
to non-myoclonus subgroup, reflecting a negative effect.
Interestingly, the percentage (%) contribution of SARAKINETIC
to SARATOTAL scores was high in the comorbid myoclonus
subgroup, compared to non-myoclonus subgroup, implicating
a predominant effect of comorbid myoclonus on SARAKINETIC,
instead of SARAGAIT/POSTURE scores. As myoclonic jerks in
GOSR2 patients may start at the upper extremities and increase
during intended kinetic limb movements, these findings are
understandable.
We are aware that this study has several limitations.
First, the EOA patients fulfilling the requirements for patient
inclusion are rare, implicating that the number of patients
was limited. However, as the present data are obtained in
a specialized movement disorder center over a study period
of 5 years (with an inclusion rate of 100%), investigation
of a larger patient cohort will not easily be accomplished.
Second, we realize that statistically significant correlations
do not necessarily implicate causality (Field, 2009). But, as
significant correlations between SARAGAIT/POSTURE sub-scores
and MF were consistently absent in patients without MF
loss, our findings do not reject causality, either. Third, to
avoid an unacceptable test burden and exhaustion for the
patients, we planned different tests during successive medical
visits to our outpatient clinic (see Supplementary Table I).
However, as latent time intervals between tests would only
exert a negative influence on the correlations, the positive
inter-correlations between SARAGAIT/POSTURE and other ataxia
biomarkers cannot be attributed to it. Fourth, we cannot exclude
that other, yet unexplored confounders may also exist (such as
neuropathy, concentration, behavior, and tiredness). Altogether,
in the perspective of the presented findings, we conclude that
SARAGAIT/POSTURE scores are associated with MF loss. In EOA
patients with comorbid myopathy, it appears prudent to interpret
SARAGAIT/POSTURE scores for the severity of muscle weakness.
CONCLUSION
The inter-observer agreement and convergent validity of
SARAGAIT/POSTURE scores in EOA patients are high, implicating
the reliability of the scores. Regarding the incomplete
discriminant validity of the scores, it is advisable to interpret
SARAGAIT/POSTURE scores for comorbid muscle weakness.
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